Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy

Anders Österborg; Juan Luis Steegmann; Andrzej Hellmann; Stephen Couban; Jiri Mayer; Joseph E. Eid

doi:10.1111/j.1365-2141.2007.06494.x

Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy

Anders Österborg, Juan Luis Steegmann, Andrzej Hellmann, Stephen Couban, Jiri Mayer, Joseph E. Eid

Pharmacology, Toxicology and Pharmaceutics

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Original language	English
Pages (from-to)	736-744
Number of pages	9
Journal	British Journal of Haematology
Volume	136
Issue number	5
DOIs	https://doi.org/10.1111/j.1365-2141.2007.06494.x
Publication status	Published - Mar 2007

ASJC Scopus Subject Areas

Hematology

Keywords

Anaemia
Chemotherapy
Continuous erythropoietin receptor activator (C.E.R.A.)
Non-Hodgkin's lymphoma
Phase II trial

Access to Document

10.1111/j.1365-2141.2007.06494.x

Cite this

Österborg, A., Steegmann, J. L., Hellmann, A., Couban, S., Mayer, J., & Eid, J. E. (2007). Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. British Journal of Haematology, 136(5), 736-744. https://doi.org/10.1111/j.1365-2141.2007.06494.x

Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. / Österborg, Anders; Steegmann, Juan Luis; Hellmann, Andrzej et al.
In: British Journal of Haematology, Vol. 136, No. 5, 03.2007, p. 736-744.

Research output: Contribution to journal › Article › peer-review

Österborg, A, Steegmann, JL, Hellmann, A, Couban, S, Mayer, J & Eid, JE 2007, 'Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy', British Journal of Haematology, vol. 136, no. 5, pp. 736-744. https://doi.org/10.1111/j.1365-2141.2007.06494.x

@article{1c51143097824b08b167bbac4474dc9f,

title = "Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy",

keywords = "Anaemia, Chemotherapy, Continuous erythropoietin receptor activator (C.E.R.A.), Non-Hodgkin's lymphoma, Phase II trial",

author = "Anders {\"O}sterborg and Steegmann, {Juan Luis} and Andrzej Hellmann and Stephen Couban and Jiri Mayer and Eid, {Joseph E.}",

year = "2007",

month = mar,

doi = "10.1111/j.1365-2141.2007.06494.x",

language = "English",

volume = "136",

pages = "736--744",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy

AU - Österborg, Anders

AU - Steegmann, Juan Luis

AU - Hellmann, Andrzej

AU - Couban, Stephen

AU - Mayer, Jiri

AU - Eid, Joseph E.

PY - 2007/3

Y1 - 2007/3

KW - Anaemia

KW - Chemotherapy

KW - Continuous erythropoietin receptor activator (C.E.R.A.)

KW - Non-Hodgkin's lymphoma

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=33846950424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846950424&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06494.x

DO - 10.1111/j.1365-2141.2007.06494.x

M3 - Article

C2 - 17313376

AN - SCOPUS:33846950424

SN - 0007-1048

VL - 136

SP - 736

EP - 744

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 5

ER -

Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy

ASJC Scopus Subject Areas

Keywords

Access to Document

Other files and links

Fingerprint

Cite this